US Patent

US10888544 — Methods for treating Gaucher disease

Method of Use · Assigned to Genzyme Corp · Expires 2038-12-13 · 13y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods for treating Gaucher disease in patients with renal or hepatic impairment.

USPTO Abstract

Methods for treating Gaucher disease in patients with renal or hepatic impairment.

Drugs covered by this patent

eliglustat-tartrate (ELIGLUSTAT TARTRATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3041`	—	eliglustat-tartrate

Patent Metadata

Patent number: US10888544
Jurisdiction: US
Classification: Method of Use
Expires: 2038-12-13
Drug substance claim: No
Drug product claim: No
Assignee: Genzyme Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.